MMWR. Morbidity and mortality weekly report · 2024
Notes from the Field: Mpox Cluster Caused by Tecovirimat-Resistant Monkeypox Virus - Five States, October 2023-February 2024.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gigante Crystal M, Takakuwa Jade, McGrath Daisy, Kling Chantal, Smith Todd G, Peng Mengfei, Wilkins Kimberly, Garrigues Jacob M, Holly Taylor, Barbian Hannah, Kittner Alyse, Haydel Danielle, Ortega Emma, Richardson Gillian, Hand Julie, Hacker Jill K, Espinosa Alex, Haw Monica, Kath Chantha, Bielby Meilan, Short Kirstin, Johnson Kimberly, De La Cruz Nelson, Davidson Whitni, Hughes Christine, Green Nicole M, Baird Nicolle, Rao Agam K, Hutson Christina L
Аннотация
The antiviral drug tecovirimat* has been used extensively to treat U.S. mpox cases since the start of a global outbreak in 2022. Mutations in the mpox viral protein target (F13 or VP37) that occur during treatment can result in resistance to tecovirimat† (1,2). CDC and public health partners have conducted genetic surveillance of monkeypox virus (MPXV) for F13 mutations through sequencing and monitoring of public databases. MPXV F13 mutations associated with resistance have been reported since 2022, typically among severely immunocompromised mpox patients who required prolonged courses of tecovirimat (3-5). A majority of patients with infections caused by MPXV with resistant mutations had a history of tecovirimat treatment; however, spread of tecovirimat-resistant MPXV was reported in California during late 2022 to early 2023 among persons with no previous tecovirimat treatment (3). This report describes a second, unrelated cluster of tecovirimat-resistant MPXV among 18 persons with no previous history of tecovirimat treatment in multiple states.